[Guest Post] Dose of reality: The Supreme Court of Canada reconciles the ban on patenting medical treatment with patents on dosing regimens
The IPKat has received and is pleased to host this guest contribution from Katfriend Jenna Park:
Dose of reality: The Supreme Court of Canada reconciles the ban on patenting medical treatment with patents on dosing regimens
by Jenna Park
A dosing regimen tells a physician how much of a drug should be administered and when. Canadian law has historically treated methods of medical treatment (“MMTs”) as unpatentable, yet patents claiming dosing regimens may be listed on the patent register and enforced against generic manufacturers. In Pharmascience Inc. v. Janssen Inc., 2026 SCC 26, a majority of seven justices reconciles this tension: the MMT exclusion survived the 1993 repeal of former s.41(1) of the Patent Act but reaches only claims that seek to monopolize professional medical skill and judgment. Two justices would have abolished the exclusion entirely. All nine upheld Janssen’s patent.
Background
Janssen’s patent claims dosing regimens for a long-acting paliperidone palmitate injection used to treat schizophrenia and related disorders: doses in the deltoid on Day 1 and Day 8 (± 2 days), then monthly (± 7 days) in the deltoid or gluteal muscle, at lower doses for patients with impaired kidney function. All 63 claims incorporate the regimens. Pharmascience argued only that they claim an MMT, proposing that anything directed to “how” and “when” a drug is given is presumptively an MMT. Janssen argued that the repeal removed the exclusion or, alternatively, that dosing regimens are inherently patentable.
The Supreme Court’s decision
The majority rejected both extreme positions, concluding that Janssen’s patent is valid.
Why the exclusion survives
The exclusion rests on the broader principle that professional skills are unpatentable, independently of s.41(1). The majority reasoned that physicians do not require patent incentives to develop or exercise their professional skills, as they are already authorised to practise their profession and are ethically bound to act in their patients’ best interests. Nothing suggests that the repeal was intended to overturn the principle established in Tennessee Eastman Co. v. Commissioner of Patents, [1974] S.C.R. 111. As the majority observed, any change to this position “must come from Parliament, not this Court”. Tennessee Eastman is the leading authority for the proposition that medical or therapeutic treatments are not patentable in Canada.
The test: professional medical skill and judgment
To determine whether a subject matter is unpatentable as an MMT, the ultimate question is whether the subject matter “amounts to professional medical skill and judgment” or seeks to “fence in” an area of medical treatment. The assessment therefore focuses on the “real subject matter” of the claims, rather than their formal wording or claim category. The Court provides three non-exhaustive points of guidance:
- The focus is whether the subject matter itself amounts to professional skill and judgment, not whether a doctor exercises judgment in selecting the treatment for a particular patient
- The more the invention must be tailored to individual patients, the more likely it is an MMT
- The more a medical professional would already be incentivized to develop or improve the subject matter in the course of their practice, the more likely it is an MMT
For dosing regimens, listing on the patent register does not confirm patentability, and fixed versus variable dosing is “at best, an evidentiary proxy that is sometimes useful but never dispositive”, and the inquiry is “factually suffused”. Janssen’s regimens survived because once a physician chooses them, no skill and judgment is needed to implement them – the choice between the two regimens is “binary” and depends on “only one aspect of the patient’s medical history” and dosing windows and injection sites “do not have clinical implications”.
Comments
What this means for claims
The decision also has implications for claim drafting. The form of a claim is not decisive: a product claim, for example, will not avoid scrutiny if its real subject matter is an MMT. In this case, the majority's analysis focused on the dosing regimens incorporated into all 63 claims. Similarly, the use of dosage ranges does not automatically render a claim unpatentable. The ±2 and ±7-day dosing windows were accepted because the evidence showed that they had no clinical significance. From a drafting perspective, defining patient subgroups through objective and measurable criteria may help distinguish a claimed regimen from one requiring the exercise of professional medical judgment. Conversely, claims requiring individual clinical assessment may face greater scrutiny.
Clinical and expert evidence showing that a regimen can be applied across a broad patient population without individual adjustment may therefore support its patentability. Conversely, parties challenging such patents may seek evidence that the regimen, as intended or actually applied, requires individualised adjustments, potentially indicating that its implementation involves professional medical skill and judgment.
What remains uncertain
How much tailoring is too much? The Court gave no threshold, only that individualization is “helpful but not determinative”, and the only example of acceptable individualization is a binary choice based on one patient characteristic.
Another unresolved question concerns the relevance of subsequent clinical practice. Although the majority considered how a regimen is “intended to be, or has been, applied”, it remains unclear how much weight should be given to actual clinical practice, particularly where some physicians depart from the claimed regimen. More broadly, the decision leaves open whether, and to what extent, changes in clinical practice over time may affect the assessment of whether a claimed regimen amounts to an MMT.
Furthermore, the third point of guidance is untested: no benchmark exists for when a physician “would already be incentivized” to develop something, and this was not discussed when considering Janssen’s patent, although Janssen’s regimen emerged from years of phased trials.
The concurrence also highlights the possibility of a different approach emerging in future cases. Two justices would have recognised MMTs as patentable in principle, finding that the rationale based on interference with professional skills presents “insurmountable issues”. Under their approach, concerns relating to skill-dependent methods would instead be addressed through the utility requirement, with reference to operability, reproducibility and control. The majority rejected this approach, warning that it could either impose a more demanding utility standard across the board or expand the scope of patentable medical treatments. Although the majority's position remains the law, the concurrence illustrates that the underlying justification for the MMT exclusion remains contested.
The MMT exclusion therefore remains firmly established in Canadian law, although its application is now more clearly defined. Unlike the United Kingdom, where the exclusion of methods of medical treatment is expressly provided for by statute, Canada's position continues to rest on judicial interpretation. The decision resolves neither the tension between patent protection and professional medical judgment nor the uncertainty surrounding its application. Instead, it confirms that the patentability of dosing regimens will continue to depend on the substance of the claims and the evidence of how they are intended to be, or have been, applied.
Image credit: Gemini
Do you want to reuse the IPKat content? Please refer to our
Policies section.
If you have any queries or requests for permission, please get in touch with the IPKat team.

Comments
Post a Comment
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html